ASH 2019 Annual Meeting Highlights in Multiple Myeloma


Shaji K. Kumar, MD
Updated Analysis of BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone, in Patients with RRMM

Begin


Shaji K. Kumar, MD
Predictive Biomarkers in the BELLINI Study: t(11;14) and High BCL2 Expression

Begin


Shaji K. Kumar, MD
Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients with RR Primary Systemic Amyloidosis

Begin


Sagar Lonial, MD, FACP
Four-Year Follow-up of the Phase 3 POLLUX Study of Dara Plus Len-Dex Versus Len-Dex Alone in RRMM

Begin


Sagar Lonial, MD, FACP
Depth of Response to Dara-RVd Improves Over Time in Patients with Transplant-Eligible Newly Diagnosed MM: GRIFFIN Study Update

Begin


Noopur Raje, MD
Findings from a Phase 1 Study of PF-06863135, a B-cell Maturation, CD3 Bispecific Antibody, in Patients with RRMM

Begin


Noopur Raje, MD
Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-BCMA CAR T-cell Therapy

Begin


Saad Z. Usmani, MD, FACP
Phase 3 Study of Subcutaneous Versus Intravenous Daratumumab Administration in Patients with RRMM: COLUMBA Updates

Begin


Saad Z. Usmani, MD, FACP
Kd-Dara Versus Kd for the Treatment of Patients with RRMM: Primary Analysis Results from the Phase 3 CANDOR Study

Begin


Saad Z. Usmani, MD, FACP
Selinexor, Pomalidomide, and Dexamethasone in Patients with RRMM

Begin